BRAF mutations occur in approximately 1%–5% of NSCLC cases, are associated with adenocarcinoma (89.3% vs. 70.6%, p = 0.048), and are more prevalent in never-smokers (78.6% vs. 56.7%, p = 0.019).58 This evidence concerns the gene BRAF and adenocarcinoma.